Published in Br J Clin Pharmacol on November 17, 2008
Torsadogenic risk of antipsychotics: combining adverse event reports with drug utilization data across Europe. PLoS One (2013) 1.13
Assessing liver injury associated with antimycotics: Concise literature review and clues from data mining of the FAERS database. World J Hepatol (2014) 0.82
QT interval shortening in spontaneous reports submitted to the FDA: the need for consensus. Br J Clin Pharmacol (2011) 0.79
American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol (2007) 7.49
Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med (2004) 6.21
International Conference on Harmonisation; guidance on E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs; availability. Notice. Fed Regist (2005) 4.86
[Ventricular tachycardia with 2 variable opposing foci]. Arch Mal Coeur Vaiss (1966) 4.21
Taking the "idio" out of "idiosyncratic": predicting torsades de pointes. Pacing Clin Electrophysiol (1998) 3.13
Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin. Pharmacotherapy (2001) 2.36
European Surveillance of Antimicrobial Consumption (ESAC): outpatient antibiotic use in Europe. J Antimicrob Chemother (2006) 2.32
Antimicrobial-associated QT interval prolongation: pointes of interest. Clin Infect Dis (2006) 2.29
QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience. Eur J Clin Pharmacol (2000) 2.05
Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG. Mol Pharmacol (2001) 1.88
National campaigns to improve antibiotic use. Eur J Clin Pharmacol (2006) 1.84
Proarrhythmia as a class effect of quinolones: increased dispersion of repolarization and triangulation of action potential predict torsades de pointes. J Cardiovasc Electrophysiol (2007) 1.68
Azithromycin-induced torsade de pointes. Pacing Clin Electrophysiol (2007) 1.67
Azithromycin as a cause of QT-interval prolongation and torsade de pointes in the absence of other known precipitating factors. J Interv Card Electrophysiol (2007) 1.65
Data mining for signals in spontaneous reporting databases: proceed with caution. Pharmacoepidemiol Drug Saf (2007) 1.61
Clinical evaluation of QT/QTc prolongation and proarrhythmic potential for nonantiarrhythmic drugs: the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use E14 guideline. J Clin Pharmacol (2006) 1.57
European surveillance of antimicrobial consumption (ESAC): data collection performance and methodological approach. Br J Clin Pharmacol (2004) 1.54
Cardiac actions of erythromycin: influence of female sex. JAMA (1998) 1.53
Effects of a new antibacterial, telavancin, on cardiac repolarization (QTc interval duration) in healthy subjects. J Clin Pharmacol (2004) 1.50
Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant "clinical" event? South Med J (2006) 1.49
Effects of three fluoroquinolones on QT interval in healthy adults after single doses. Clin Pharmacol Ther (2003) 1.46
Organising evidence on QT prolongation and occurrence of Torsades de Pointes with non-antiarrhythmic drugs: a call for consensus. Eur J Clin Pharmacol (2001) 1.45
QTc and psychotropic drugs. Lancet (2000) 1.44
QT prolongation through hERG K(+) channel blockade: current knowledge and strategies for the early prediction during drug development. Med Res Rev (2005) 1.42
Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes. J Pharmacol Exp Ther (2002) 1.39
Torsade de pointes probably induced by sparfloxacin. J Assoc Physicians India (2002) 1.39
Variability in the measurement of hERG potassium channel inhibition: effects of temperature and stimulus pattern. J Pharmacol Toxicol Methods (2004) 1.33
A case of QT-interval prolongation precipitated by azithromycin. N Z Med J (2003) 1.30
Blockade of human cardiac potassium channel human ether-a-go-go-related gene (HERG) by macrolide antibiotics. J Pharmacol Exp Ther (2002) 1.30
Drugs, QTc interval prolongation and final ICH E14 guideline : an important milestone with challenges ahead. Drug Saf (2005) 1.29
Can pharmacogenetics help rescue drugs withdrawn from the market? Pharmacogenomics (2006) 1.27
Azithromycin-induced QT prolongation in elderly patient. Acta Biomed (2006) 1.23
The hERG K+ channel: target and antitarget strategies in drug development. Pharmacol Res (2008) 1.22
Antibiotic use in ambulatory care in Europe (ESAC data 1997-2002): trends, regional differences and seasonal fluctuations. Pharmacoepidemiol Drug Saf (2007) 1.21
Polymorphic ventricular tachycardia with a normal QT interval following azithromycin. Pacing Clin Electrophysiol (2005) 1.19
Quinolone-induced QT interval prolongation: a not-so-unexpected class effect. J Antimicrob Chemother (2000) 1.16
QT prolongation with antimicrobial agents: understanding the significance. Drugs (2004) 1.14
Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections. Drugs (2000) 1.14
Characterization of the inhibitory effects of erythromycin and clarithromycin on the HERG potassium channel. Mol Cell Biochem (2003) 1.12
Effects of three fluoroquinolones on QT analysis after standard treatment courses. Ann Noninvasive Electrocardiol (2006) 1.07
Mechanism of hERG K+ channel blockade by the fluoroquinolone antibiotic moxifloxacin. Br J Pharmacol (2006) 1.07
QT prolongation and proarrhythmia by moxifloxacin: concordance of preclinical models in relation to clinical outcome. Br J Pharmacol (2005) 1.02
Measuring the effects of supratherapeutic doses of levofloxacin on healthy volunteers using four methods of QT correction and periodic and continuous ECG recordings. J Clin Pharmacol (2004) 1.02
Differentiation of arrhythmia risk of the antibacterials moxifloxacin, erythromycin, and telithromycin based on analysis of monophasic action potential duration alternans and cardiac instability. J Pharmacol Exp Ther (2006) 1.01
QT PRODACT: in vivo QT assay in the conscious dog for assessing the potential for QT interval prolongation by human pharmaceuticals. J Pharmacol Sci (2005) 1.00
Moxifloxacin and torsade de pointes. Ann Pharmacother (2007) 0.98
In-vitro experimental models for the risk assessment of antibiotic-induced QT prolongation. Eur J Pharmacol (2007) 0.98
In vivo experimental approach for the risk assessment of fluoroquinolone antibacterial agents-induced long QT syndrome. Eur J Pharmacol (2004) 0.97
Clinical pharmacokinetics of telithromycin, the first ketolide antibacterial. Clin Pharmacokinet (2005) 0.97
Ciprofloxacin-induced torsade de pointes. Int J Cardiol (2005) 0.96
Potential use of data-mining algorithms for the detection of 'surprise' adverse drug reactions. Drug Saf (2007) 0.94
Exaggerated block of hERG (KCNH2) and prolongation of action potential duration by erythromycin at temperatures between 37 degrees C and 42 degrees C. Heart Rhythm (2005) 0.94
A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community-acquired pneumonia. Chest (2005) 0.93
No proarrhythmic properties of the antibiotics Moxifloxacin or Azithromycin in anaesthetized dogs with chronic-AV block. Br J Pharmacol (2006) 0.93
Ciprofloxacin-induced acquired long QT syndrome. Heart Rhythm (2004) 0.93
Human ether-a-go-go-related (HERG) gene and ATP-sensitive potassium channels as targets for adverse drug effects. Pharmacol Ther (2006) 0.93
Torsade de pointes associated with moxifloxacin: a rare but potentially fatal adverse event. Can J Cardiol (2007) 0.91
Studies on the mechanism of a fatal clarithromycin-pimozide interaction in a patient with Tourette syndrome. J Clin Psychopharmacol (2000) 0.91
Non-antiarrhythmic drugs prolonging the QT interval: considerable use in seven countries. Br J Clin Pharmacol (2002) 0.89
Erythromycin block of the HERG K+ channel: accessibility to F656 and Y652. Biochem Biophys Res Commun (2006) 0.88
Comparative assessment of prurifloxacin, sparfloxacin, gatifloxacin and levofloxacin in the rabbit model of proarrhythmia. J Toxicol Sci (2004) 0.88
Retrospective analysis of the safety profile of oral moxifloxacin in elderly patients enrolled in clinical trials. Drug Saf (2005) 0.87
The more antibacterial trade names, the more consumption of antibacterials: a European study. Clin Infect Dis (2005) 0.86
[Ventricular tachycardia and long QT associated with clarithromycin administration in a patient with HIV infection]. Rev Esp Cardiol (2002) 0.86
QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine. Ann Pharmacother (2005) 0.86
Drug-induced QT interval prolongation after ciprofloxacin administration in a patient receiving olanzapine. Int J Cardiol (2005) 0.86
Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors. Clin Infect Dis (2002) 0.85
Effect of single and repeated oral doses of telithromycin on cardiac QT interval in healthy subjects. Clin Pharmacol Ther (2003) 0.85
Life-threatening bradyarrhythmia after massive azithromycin overdose. Pharmacotherapy (2006) 0.85
Data mining in pharmacovigilance: the need for a balanced perspective. Drug Saf (2005) 0.84
A highly sensitive canine telemetry model for detection of QT interval prolongation: studies with moxifloxacin, haloperidol and MK-499. J Pharmacol Toxicol Methods (2007) 0.84
Comparison of guinea-pig ventricular myocytes and dog Purkinje fibres for in vitro assessment of drug-induced delayed repolarization. J Pharmacol Toxicol Methods (2007) 0.83
Clarithromycin induced torsade de pointes. Ir J Med Sci (2007) 0.82
A new respiratory fluoroquinolone, oral gemifloxacin: a safety profile in context. Int J Antimicrob Agents (2004) 0.82
Fluconazole- and levofloxacin-induced torsades de pointes in an intensive care unit patient. Am J Health Syst Pharm (2003) 0.81
Electrophysiological safety of novel fluoroquinolone antibiotic agents gemifloxacin and balofloxacin. Drug Chem Toxicol (2006) 0.81
Prulifloxacin: in vitro (HERG current) and in vivo (conscious dog) assessment of cardiac risk. Eur J Pharmacol (2003) 0.81
QT prolongation and torsades de pointes associated with concurrent use of cisapride and erythromycin. Am J Otolaryngol (2002) 0.81
Telithromycin: the first ketolide antimicrobial. Clin Ther (2005) 0.80
Torsades de pointes associated with fluoroquinolones: importance of concomitant risk factors. Clin Pharmacol Ther (2004) 0.80
Applying quantitative methods for detecting new drug safety signals in pharmacovigilance national database. Pharmacoepidemiol Drug Saf (2007) 0.79
Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis. Am J Ther (2004) 0.79
Effects of fluoroquinolones on HERG channels and on pancreatic beta-cell ATP-sensitive K+ channels. Toxicology (2006) 0.79
QT PRODACT: sensitivity and specificity of the canine telemetry assay for detecting drug-induced QT interval prolongation. J Pharmacol Sci (2005) 0.79
Levofloxacin induced polymorphic ventricular tachycardia with normal QT interval. Pacing Clin Electrophysiol (2001) 0.79
Risk of torsades de pointes with non-cardiac drugs. Prolongation of QT interval is probably a class effect of fluoroquinolones. BMJ (2001) 0.79
Choice of cardiac tissue in vitro plays an important role in assessing the risk of drug-induced cardiac arrhythmias in human: beyond QT prolongation. J Pharmacol Toxicol Methods (2007) 0.78
Acute respiratory distress syndrome with transiently impaired left ventricular function and Torsades de Pointes arrhythmia unmasking congenital long QT syndrome in a 25-yr-old woman. Br J Anaesth (2006) 0.78
Choice of cardiac tissue plays an important role in the evaluation of drug-induced prolongation of the QT interval in vitro in rabbit. J Pharmacol Toxicol Methods (2005) 0.78
The effects of levofloxacin on ECG parameters and late potentials. Am J Ther (2005) 0.78
Effect of ketoconazole on the pharmacokinetics and safety of telithromycin and clarithromycin in older subjects with renal impairment. Int J Clin Pharmacol Ther (2005) 0.78
Roxithromycin induced torsade de pointes in a patient with complex congenital heart disease and complete atrioventricular block. Pacing Clin Electrophysiol (2003) 0.78
Acute hypokalemia may not be an effective way to sensitize the in situ canine heart for sparfloxacin-induced long QT syndrome. J Pharmacol Sci (2006) 0.77
Application of a probabilistic method for the determination of drug-induced QT prolongation in telemetered cynomolgus monkeys: effects of moxifloxacin. J Pharmacol Toxicol Methods (2006) 0.77
Quinolone-induced QT interval prolongation: a not-so-unexpected class effect. J Antimicrob Chemother (2001) 0.76
Inhibitory effect of erythromycin on potassium currents in rat ventricular myocytes in comparison with disopyramide. J Pharm Pharmacol (2003) 0.76
Gatifloxacin and prolonged QT interval. Am J Med Sci (2004) 0.76
Gatifloxacin induced torsades de pointes. Pacing Clin Electrophysiol (2004) 0.76
Roxithromycin-induced torsades de pointes. Eur J Intern Med (2004) 0.76
[QT prolongation and ventricular tachycardia due to roxithromycin]. Anadolu Kardiyol Derg (2005) 0.76
Antibiotic resistance-the need for global solutions. Lancet Infect Dis (2013) 15.01
EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology (2012) 4.83
International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial Infections. Ann Intern Med (2004) 4.75
Amoxicillin for acute lower-respiratory-tract infection in primary care when pneumonia is not suspected: a 12-country, randomised, placebo-controlled trial. Lancet Infect Dis (2012) 4.62
Community-acquired Klebsiella pneumoniae bacteremia: global differences in clinical patterns. Emerg Infect Dis (2002) 4.08
European Position Paper on Rhinosinusitis and Nasal Polyps 2012. Rhinol Suppl (2012) 3.98
Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin Infect Dis (2004) 3.75
Characteristics and outcomes of public campaigns aimed at improving the use of antibiotics in outpatients in high-income countries. Lancet Infect Dis (2010) 3.65
Ready for a world without antibiotics? The Pensières Antibiotic Resistance Call to Action. Antimicrob Resist Infect Control (2012) 3.02
Antimicrobial drug use and resistance in Europe. Emerg Infect Dis (2008) 2.68
European Surveillance of Antimicrobial Consumption (ESAC): outpatient antibiotic use in Europe (1997-2009). J Antimicrob Chemother (2011) 2.58
Society's failure to protect a precious resource: antibiotics. Lancet (2011) 2.51
Virulence characteristics of Klebsiella and clinical manifestations of K. pneumoniae bloodstream infections. Emerg Infect Dis (2007) 2.49
Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut (2012) 2.49
European Surveillance of Antimicrobial Consumption (ESAC): outpatient antibiotic use in Europe. J Antimicrob Chemother (2006) 2.32
A potential virulence gene, hylEfm, predominates in Enterococcus faecium of clinical origin. J Infect Dis (2003) 2.29
Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. Diabetes Care (2011) 2.16
Development of a multiplex PCR for the detection of asa1, gelE, cylA, esp, and hyl genes in enterococci and survey for virulence determinants among European hospital isolates of Enterococcus faecium. J Clin Microbiol (2004) 2.10
Antibiotic use varies substantially among adults: a cross-national study from five European Countries in the ARITMO project. Infection (2015) 2.06
Prevalence and resistance of commensal Staphylococcus aureus, including meticillin-resistant S aureus, in nine European countries: a cross-sectional study. Lancet Infect Dis (2013) 2.04
Appropriate international measures for outpatient antibiotic prescribing and consumption: recommendations from a national data comparison of different measures. J Antimicrob Chemother (2013) 2.04
Inflammatory neuropathies of the enteric nervous system. Gastroenterology (2004) 2.02
Comparison and evaluation of real-time PCR, real-time nucleic acid sequence-based amplification, conventional PCR, and serology for diagnosis of Mycoplasma pneumoniae. J Clin Microbiol (2003) 1.87
Evaluation of real-time PCR for detection of and discrimination between Bordetella pertussis, Bordetella parapertussis, and Bordetella holmesii for clinical diagnosis. J Clin Microbiol (2003) 1.85
Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination. Proc Natl Acad Sci U S A (2010) 1.84
Identification of a novel plasmid-mediated colistin-resistance gene, mcr-2, in Escherichia coli, Belgium, June 2016. Euro Surveill (2016) 1.84
Current trends in rapid diagnostics for methicillin-resistant Staphylococcus aureus and glycopeptide-resistant enterococcus species. J Clin Microbiol (2008) 1.81
Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview. Drug Saf (2002) 1.62
In vitro antibacterial activity of the ceftazidime-avibactam (NXL104) combination against Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother (2012) 1.59
Enteric neuroplasticity evoked by inflammation. Auton Neurosci (2006) 1.55
The European surveillance of antimicrobial consumption (ESAC) point-prevalence survey of antibacterial use in 20 European hospitals in 2006. Clin Infect Dis (2009) 1.53
Surveillance of outpatient antibiotic consumption in Spain according to sales data and reimbursement data. J Antimicrob Chemother (2007) 1.53
Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the US FDA Adverse Event Reporting System. Drug Saf (2010) 1.53
Current trends in culture-based and molecular detection of extended-spectrum-β-lactamase-harboring and carbapenem-resistant Enterobacteriaceae. J Clin Microbiol (2012) 1.52
Effect of generics on price and consumption of ciprofloxacin in primary healthcare: the relationship to increasing resistance. J Antimicrob Chemother (2010) 1.51
Isolation and characterization of current human coronavirus strains in primary human epithelial cell cultures reveal differences in target cell tropism. J Virol (2013) 1.47
Triptans and serious adverse vascular events: data mining of the FDA Adverse Event Reporting System database. Cephalalgia (2013) 1.47
Evaluation of new broth media for microdilution antibiotic susceptibility testing of Lactobacilli, Pediococci, Lactococci, and Bifidobacteria. Appl Environ Microbiol (2005) 1.47
Severity assessment for lower respiratory tract infections: potential use and validity of the CRB-65 in primary care. Prim Care Respir J (2012) 1.46
A systematic review and meta-analysis of the effects of antibiotic consumption on antibiotic resistance. BMC Infect Dis (2014) 1.46
Towards clinical definitions of lower respiratory tract infection (LRTI) for research and primary care practice in Europe: an international consensus study. Prim Care Respir J (2011) 1.45
Evaluation of 12 commercial tests and the complement fixation test for Mycoplasma pneumoniae-specific immunoglobulin G (IgG) and IgM antibodies, with PCR used as the "gold standard". J Clin Microbiol (2005) 1.45
Detection of Mycoplasma pneumoniae in respiratory samples by real-time PCR using an inhibition control. J Microbiol Methods (2003) 1.44
Multiplex PCR for simultaneous detection of macrolide and tetracycline resistance determinants in streptococci. Antimicrob Agents Chemother (2005) 1.42
QT prolongation through hERG K(+) channel blockade: current knowledge and strategies for the early prediction during drug development. Med Res Rev (2005) 1.42
Intestinal serotonin release, sensory neuron activation, and abdominal pain in irritable bowel syndrome. Am J Gastroenterol (2011) 1.41
Development and clinical evaluation of an internally controlled, single-tube multiplex real-time PCR assay for detection of Legionella pneumophila and other Legionella species. J Clin Microbiol (2003) 1.40
Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS). Pharmacoepidemiol Drug Saf (2009) 1.39
'The body gets used to them': patients' interpretations of antibiotic resistance and the implications for containment strategies. J Gen Intern Med (2011) 1.39
Sales of veterinary antibacterial agents in nine European countries during 2005-09: trends and patterns. J Antimicrob Chemother (2012) 1.36
Community acquired pneumonia in primary care. BMJ (2006) 1.35
A sensitive assay for virus discovery in respiratory clinical samples. PLoS One (2011) 1.33
European Surveillance of Antimicrobial Consumption (ESAC): quality indicators for outpatient antibiotic use in Europe. Qual Saf Health Care (2007) 1.32
Antimicrobial susceptibilities of Lactobacillus, Pediococcus and Lactococcus human isolates and cultures intended for probiotic or nutritional use. J Antimicrob Chemother (2007) 1.32
Differences in gut microbiota composition between obese and lean children: a cross-sectional study. Gut Pathog (2013) 1.30
Evaluation of chromogenic media for detection of methicillin-resistant Staphylococcus aureus. J Clin Microbiol (2010) 1.30
Therapeutic innovation in the European Union: analysis of the drugs approved by the EMEA between 1995 and 2003. Br J Clin Pharmacol (2005) 1.30
European Surveillance of Antimicrobial Consumption (ESAC): outpatient quinolone use in Europe. J Antimicrob Chemother (2006) 1.29
European Surveillance of Antimicrobial Consumption (ESAC): disease-specific quality indicators for outpatient antibiotic prescribing. BMJ Qual Saf (2011) 1.27
Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers. J Med Chem (2002) 1.27
Antibiotics for acute cough: an international observational study of patient adherence in primary care. Br J Gen Pract (2012) 1.25
Antipsychotics and torsadogenic risk: signals emerging from the US FDA Adverse Event Reporting System database. Drug Saf (2013) 1.24
An update on the first decade of the European centralized procedure: how many innovative drugs? Br J Clin Pharmacol (2006) 1.23
Discontinuation of and changes in drug therapy for hypertension among newly-treated patients: a population-based study in Italy. J Hypertens (2008) 1.23
Identification of targets for quality improvement in antimicrobial prescribing: the web-based ESAC Point Prevalence Survey 2009. J Antimicrob Chemother (2010) 1.23
The hERG K+ channel: target and antitarget strategies in drug development. Pharmacol Res (2008) 1.22
Clinical and morphofunctional features of idiopathic myenteric ganglionitis underlying severe intestinal motor dysfunction: a study of three cases. Am J Gastroenterol (2002) 1.22
Antibiotic use in ambulatory care in Europe (ESAC data 1997-2002): trends, regional differences and seasonal fluctuations. Pharmacoepidemiol Drug Saf (2007) 1.21
Association between antibiotic sales and public campaigns for their appropriate use. JAMA (2004) 1.20
Anti-HuD-induced neuronal apoptosis underlying paraneoplastic gut dysmotility. Gastroenterology (2003) 1.19
A multi-country qualitative study of clinicians' and patients' views on point of care tests for lower respiratory tract infection. Fam Pract (2011) 1.16
General practitioners' views on the acceptability and applicability of a web-based intervention to reduce antibiotic prescribing for acute cough in multiple European countries: a qualitative study prior to a randomised trial. BMC Fam Pract (2012) 1.15
Primary care clinicians' perceptions of antibiotic resistance: a multi-country qualitative interview study. J Antimicrob Chemother (2012) 1.15
Herpes simplex virus in the respiratory tract of critical care patients: a prospective study. Lancet (2003) 1.15
The beta3-adrenoceptor as a therapeutic target: current perspectives. Pharmacol Res (2009) 1.13
Torsadogenic risk of antipsychotics: combining adverse event reports with drug utilization data across Europe. PLoS One (2013) 1.13
Clonal spread of fluoroquinolone non-susceptible Streptococcus pyogenes. J Antimicrob Chemother (2005) 1.12
Macrolide- and telithromycin-resistant Streptococcus pyogenes, Belgium, 1999-2003. Emerg Infect Dis (2005) 1.12
Diagnostics as essential tools for containing antibacterial resistance. Drug Resist Updat (2011) 1.12
Are patient views about antibiotics related to clinician perceptions, management and outcome? A multi-country study in outpatients with acute cough. PLoS One (2013) 1.11
Comparison of strategies to reduce meticillin-resistant Staphylococcus aureus rates in surgical patients: a controlled multicentre intervention trial. BMJ Open (2013) 1.11
Bacitracin-resistant clone of Streptococcus pyogenes isolated from pharyngitis patients in Belgium. J Clin Microbiol (2003) 1.10
Clinicians' views and experiences of interventions to enhance the quality of antibiotic prescribing for acute respiratory tract infections. J Gen Intern Med (2014) 1.10
European Surveillance of Antimicrobial Consumption (ESAC): quality appraisal of antibiotic use in Europe. J Antimicrob Chemother (2011) 1.10
Pattern of NSAID use in the Italian general population: a questionnaire-based survey. Eur J Clin Pharmacol (2004) 1.10
Priority actions to fight antibiotic resistance: results of an international meeting. Antimicrob Resist Infect Control (2012) 1.10
Comment on: "Pharmacokinetics in patients with chronic liver disease and hepatic safety of incretin-based therapies for the management of type 2 diabetes mellitus". Clin Pharmacokinet (2015) 1.09